Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23587032 | 0.90 | CYP2A6 (0.42) | SMN1; SMN2ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL17736028 | 0.89 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1LMNACYP1A1CYP1A2 | |
| SCHEMBL1598510 | 0.85 | MEN1 (0.44) | SMN1; SMN2ALDH1A1LMNACYP1A1GAA | |
| SCHEMBL16061977 | 0.83 | CCNC (0.40) | SMN1; SMN2ALDH1A1LMNACYP1A1CYP1A2 | |
| SCHEMBL4672007 | 0.81 | LTA4H (0.42) | LMNACYP1A2NPC1MAPTNAMPT | |
| SCHEMBL16092097 | 0.80 | CDC25B (0.48) | SMN1; SMN2ALDH1A1LMNACYP1A2KDM4E | |
| SCHEMBL11740036 | 0.76 | LMNA (0.53) | SMN1; SMN2ALDH1A1LMNAGAANPC1 | |
| SCHEMBL1375091 | 0.74 | LMNA (0.57) | SMN1; SMN2ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL21243066 | 0.73 | CYP2A6 (0.37) | SMN1; SMN2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL31478197 | 0.73 | LMNA (0.50) | SMN1; SMN2ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842424-B1 | MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES | UNIV COLUMBIA (US) | 2024-12-11 | — | — | EP | disclosed |
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-11149020-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-19 | — | — | US | disclosed |
| US-11149020-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3842424-A1 | MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES | The Trustees of Columbia University in the City of New York (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3521284-B1 | PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3521284-B1 | PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-05-12 | — | — | US | disclosed |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-05-12 | — | — | US | disclosed |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-05-12 | — | — | US | disclosed |
| EP-2968322-A2 | MAP KINASE MODULATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145485-A2 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145485-A2 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | WO | disclosed |
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1506186-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | SMN1; SMN2 103/4885ALDH1A1 2033/4885LMNA 1813/4885 |
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | SMN1; SMN2 103/4885ALDH1A1 2033/4885LMNA 1813/4885 |
| US-11149020-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | SMN1; SMN2 103/4885ALDH1A1 2033/4885LMNA 1813/4885 |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | SMN1; SMN2 7/4885ALDH1A1 2237/4885LMNA 3885/4885 |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | SMN1; SMN2 103/4885ALDH1A1 2033/4885LMNA 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.